(EMAILWIRE.COM, July 30, 2008 ) Los Angeles, CA -- July 29th, 2008 -- StockProfit.com today announced it has begun profile coverage of HSTC Global, Inc. (OTCBB: HSTC), a development stage biotechnology company. The entire profile can be viewed at http://www.stockprofit.com/company.

HST Global, Inc., (OTCBB: HSTC), announced today it is meeting with 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients. The highlight of the study is in stage IV breast cancer where they have met with 72% efficacy with 58 patients over 2 ½ years with its drug candidate Salicinium.

Ronald Howell, President & CEO of HST Global, Inc. stated, "We are encouraged by these results and are looking forward to subjecting the study to more rigorous tests to support eventual commercialization."

About the Study:

HST Global, Inc., currently has the rights to a pre-clinical outcome-based study using the pre-clinical drug trade named “Salicinium”. This natural substance, which is plant-derived, is both oral and a parenteral active inhibitor of certain fermenting enzyme dynamics in the cancer cells. Clinical studies demonstrate that Salicinium alters malignant cell fermentation dynamics, blocks cell division (mitosis), and causes fermenting cancer cells to lose their ability to withstand innate immune reactions.

Given parenterally, in the form of the Forsythe Immune Therapy #2, the I.V. contains proprietary amounts of normal saline, magnesium chloride, vitamin B6, vitamin B12, B complex, folic acid, vitamin C, L-Lysine, zinc, glutathione, and the main ingredient “Salicinium”. The preparation is succussed at the time of the patient’s visit, and it is prepared in approximately a 1:70 dilution.

The purpose of the pre-clinical outcome-based study in Stage IV adult cancers is to study efficacy and safety issues. All patients coming to the clinical are given the following choices:
1. Conventional chemotherapy, either first, second or third line, as appropriate to the patient’s prior history.
2. Conventional chemotherapy, either standard or low-dose fractioned, with Salicinium;
3. Conventional dose or low-dose fractioned chemotherapy with Salicinium and other complimentary products;
4. Salicinium along with other complimentary therapies;
5. Salicinium alone;
6. Insulin potentiated therapy using standard chemotherapy with Salicinium; and
7. Any of the above plus hormonal therapies.

This study was carried out from June of 2005 through March of 2008, with 250 Stage IV cancer patients under study.

The advantages of the pre-clinical study were to show efficacy and safety, and freedom from adverse toxicities and adverse side-effects. The conclusion of the study was that Salicinium is a novel, homeopathic, immune boosting therapy that when used alone in breast cancer, isolated from other cancers, showed an overall response rate of 79% at 33 months.

When Salicinium was used in combination with Poly-MVA and/or chemotherapy, the overall response rate was 75%.

These results compared favorably with conventional chemotherapy alone which, in five years in the allopathic literature from 2004, showed only a 2.1% survival rate in the United States with any form of chemotherapy alone.

It is important to note that this product is compatible with other complimentary therapies, which vector in on the metabolism of the cancer cell in a different matter.

Also of great importance is the fact that there were no significant adverse events in these 250 patients using Salicinium, even when used with low-dose fractioned chemotherapy.

The pre-clinical outcome-based study is available for review, with all the statistics outline, which demonstrates the above positive effects.

HST Global, Inc. makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

About HST Global, Inc.

HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use.

Contact:
HST Global, Inc
Investor Relations
Wesley Tate (757)-766-6100
ir@hstglobal.com
www.hstglobal.com

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


About StockProfit.com

StockProfit.com specializes in using technical analysis to identify stocks in particularly powerful up-trends, then pinpoint the optimal time to enter these stocks. Additionally, StockProfit.com is an online resource for aggressive risk-tolerant market participants who wish to learn about select growth companies and other ideas that could offer potentially superior investment returns. Research and due diligence tools such as Company Profiles, Technical Trading Alerts, detailed investment opinion reports, and regular email updates of Featured Companies are some of the services we provide to our readership. For more information, visit http://www.stockprofit.com

-----------------------------------------------------------------------------------------------------
Special Offer: The StockProfit Momentum Stock Trader by Tony Golan is a nightly email letter, including broad market analysis, intermediate-term trades, swing trades and daytrades. All trades include clear, concise trading instructions, spelling for you exactly where to buy, how to place your order, where to place your protective sell-stop and when to sell. The Momentum Stock Trader concentrates only on the strongest momentum stocks in the market. Subscribe now and begin benefiting from the strong stocks uncovered by Tony Golan’s RSD indicator at http://www.stockprofit.com/trades
-----------------------------------------------------------------------------------------------------

Disclaimer: Copyright© 2008 StockProfit™. All rights reserved. StockProfit™ is an independent electronic publication providing information on select public companies. StockProfit™ is not a registered investment advisor or broker-dealer. There is a risk of loss in all of trading. Past performance is no indication, nor guarantee of future results. The information contained herein is believed to be accurate. This update is provided as an information service only, and the statements and opinions in this update should not be construed as an offer or solicitation to buy or sell any security. In no event shall StockProfit™ and/or its publisher, P.A. Relations or any of its employees or affiliates, be liable for any direct, incidental, consequential, indirect or punitive damages whatsoever arising out of the use of the Information, or for any errors or omissions in the content thereof, including, but not limited to, from any investment loss, damage or expense incurred by any investor resulting from the Information, or from the purchase or sale of any profiled company or any company which we make commentary. We recommend using good-'till-cancelled stop orders to minimize losses in the event of an adverse price movement. we have been compensated $ 2,500 and expect to receive 27,500 Rule 144 shares by the Company for Profile Coverage. For further information, please visit http://www.stockprofit.com/disclaimer/

CONTACT: Alan Klitenic , P.A. Relations TEL: 818 334 4469 EMAIL: amk@stockprofit.com

Contact Information:
P.A. Relations
Alan Klitenic
Tel: 818-334-4469
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.